Analytical Method and Validation for Estimation of Vonoprazan in Pharmaceutical Dosage Form – A Review

Vonoprazan is a first in class potassium competitive acid blocker (P-CAB) approved by the U.S. Food and Drug Administration(FDA) for the treatment of helicobacter pylori infection in adults. H+\K+ATP ase proton pump,vonaprazan compatetively and reversibely blocks potassium binding on the proton pump,resulting in more rapid,potent and sustained acid suppression. Additionally , vonoprazan shows promise in managing PPI-resistance gastroesophageal reflux disease (GIRD). Peptic ulcer in the combination regimens for helicobacter pylori eradication. Vonopazan offers faster onset of action, prolonged acid suppression and improved patient outcomes compared to PPI’S. clinical trails have demonstrated higher eradication rates with vonoprazan – based triple therapy, even in patients with clarithromycin resistant strains, which is a key advantages in reducing progression of chronic gastritis to gastric cancer. In long term studies are warranted to establish its role in reducing gastric cancer. While vonoprazan has not been directly linked to COVID-19 outcomes, its pharmacological properties suggest potential utility in supporting gastrointestinal management in infected patient. Its stability in acidic environments and independence from metabolic variability provide advantages in critically ill patients, including those receiving multiple medications during COVID-19 treatment. Vonoprazan offers faster onset of action, prolonged acid suppression, and improved patient outcomes compared to PPI’s. with its favorable pharmacokinetic profile and safety data, vonoprazan represent a significant advancement in the treatment of acid-related diseases, though long term safety evaluation and border clinical use are still under investigation.